Breast Cancer Research and Treatment

, Volume 98, Issue 2, pp 167–172

Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer

  • Harriet Johansson
  • Bernardo Bonanni
  • Frederique Mariette
  • Massimiliano Cazzaniga
  • Laura Baglietto
  • Aliana Guerrieri-Gonzaga
  • Maria Teresa Sandri
  • Alberto Luini
  • Giuseppe Pelosi
  • Andrea Decensi
Clinical trial
  • 54 Downloads

Summary

Within a multicentric, double-blind, placebo-controlled phase II trial, postmenopausal women with primary breast cancer were randomized to either 60 or 600 mg daily of raloxifene or placebo administered for 2 weeks prior to surgery. Circulating levels of sex-hormone binding globulin (SHBG), dehydroepiandrosterone-sulfate (DHEA-S), estrone (E1), estrone-sulfate (E1-S), estradiol (E2), and C-terminal telopeptide (CTX), were determined at baseline and the day before surgery in 37 women enrolled at the European Institute of Oncology in Milan. Raloxifene had a statistically significant different effect compared with placebo on SHBG (p<0.001) and E2 (p=0.03), without any dose–response relationship. Women on raloxifene (n=26) showed an increase from baseline of 10.7% (inter-quartile range: 5.9; 24.2) in SHBG and of 1.3% (inter-quartile range: −8.0; 24.5) in E2, whereas women on placebo (n=11) showed a decrease by 15.5% (inter-quartile range: 7.9; 18.1) and 17.3% (inter-quartile range: 6.5; 40.0), respectively. No significant differences were found on the other variables. A positive correlation was observed between DHEA-S and E1-S (p=0.001) or E2 (p<0.001), while SHBG correlated negatively with E1-S (p=0.024) and E2 (p=0.01), and positively with DHEA-S (p=0.016) and CTX (p=0.040). Our results provide evidence for an early endocrine effect of raloxifene which further suggests a favorable impact on breast cancer prevention.

Keywords

biomarkers bone resorption breast cancer chemoprevention estrogen raloxifene 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsJAMA 282: 637–645PubMedCrossRefGoogle Scholar
  2. 2.
    Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal womenN Engl J Med 337: 1641–1647PubMedCrossRefGoogle Scholar
  3. 3.
    Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW 1998 Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal womenJAMA 279: 1445–1451PubMedCrossRefGoogle Scholar
  4. 4.
    Cox DA, Sarkar S, Harper K, Barrett-Connor E 2004 Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal womenCurr Med Res Opin 20: 1049–1055PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen FJ, Watts S, Shah A, Akers R, Plouffe L Jr 2000 Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60Obstet Gynecol 95: 104–110PubMedCrossRefGoogle Scholar
  6. 6.
    Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC, 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation JAMA 281: 2189–2197PubMedCrossRefGoogle Scholar
  7. 7.
    Goldstein SR, 2000 Update on raloxifene to prevent endometrial-breast cancer Eur J Cancer 36 Suppl 4: S54–S56PubMedCrossRefGoogle Scholar
  8. 8.
    Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, Winter MA, Yang NN, Dodge JA 1997 Molecular determinants of tissue selectivity in estrogen receptor modulatorsProc Natl Acad Sci USA 94: 14105–14110PubMedCrossRefGoogle Scholar
  9. 9.
    Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR, CORE Investigators, 2004 Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifeneJ Natl Cancer Inst 96: 1751–1761PubMedGoogle Scholar
  10. 10.
    Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P, 2003 Overview of the main outcomes in breast-cancer prevention trialsLancet 361: 296–300PubMedCrossRefGoogle Scholar
  11. 11.
    Vogel VG, Costantino JP, Wickerham DL, Cronin WM, 2003 National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situClin Cancer Res 9: 495S–501SPubMedGoogle Scholar
  12. 12.
    Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW Jr, 2000 Effects of high dose raloxifene in selected patients with advanced breast carcinomaCancer 88: 2047–2053PubMedCrossRefGoogle Scholar
  13. 13.
    Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien ME, Scott T, Muchmore DB, 2001 Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patientsCancer Epidemiol Biomarkers Prev 10: 961–966PubMedGoogle Scholar
  14. 14.
    Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, IMPACT Trialists, 2005 Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survivalClin Cancer Res 11: 951s–958sPubMedGoogle Scholar
  15. 15.
    Key T, Appleby P, Barnes I, Reeves G,Endogenous Hormones and Breast Cancer Collaborative Group 2002 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies J Natl Cancer Inst 94: 606–616PubMedGoogle Scholar
  16. 16.
    Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA,Multiple Outcomes of Raloxifene Evaluation (MORE) Trial, 2002 Serum estradiol level and risk of breast cancer during treatment with raloxifeneJAMA 287: 216–220PubMedCrossRefGoogle Scholar
  17. 17.
    Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, Cauley JA, Cummings SR, 2001 Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participantsJ Clin Oncol 19: 3111–3116PubMedGoogle Scholar
  18. 18.
    Chailurkit LO, Ongphiphadhanakul B, Piaseu N, Saetung S, Rajatanavin R, 2001 Biochemical markers of bone turnover and response of bone mineral density to intervention in early postmenopausal women: an experience in a clinical laboratoryClin Chem 47: 1083–1088PubMedGoogle Scholar
  19. 19.
    Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD, 2000 Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS studyBone 27: 283–286PubMedCrossRefGoogle Scholar
  20. 20.
    Kelloff GJ, Bast RC Jr., Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Woude GF, 2004 Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologueClin Cancer Res 10: 3881–3884PubMedCrossRefGoogle Scholar
  21. 21.
    Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P, Torrisi R, Cazzaniga M, Mora S, Sandri MT, Pelosi G, Luini A, Goldhirsch A, Lien EA, Veronesi U, 2003 A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkersJ Natl Cancer Inst 95: 779–790PubMedCrossRefGoogle Scholar
  22. 22.
    Catalano MG, Frairia R, Boccuzzi G, Fortunati N, 2005 Sex hormone-binding globulin antagonizes the anti-apoptotic effect of estradiol in breast cancer cellsMol Cell Endocrinol 230: 31–37PubMedCrossRefGoogle Scholar
  23. 23.
    Genazzani AR, Lombardi I, Borgioli G, di Bono I, Casarosa E, Gambacciani M, Palumbo M, Genazzani AD, Luisi M, 2003 Adrenal function under long-term raloxifene administrationGynecol Endocrinol 17: 159–168PubMedCrossRefGoogle Scholar
  24. 24.
    Reindollar R, Koltun W, Parsons A, Study Group on the Effects of Raloxifene HCI With Low-Dose Premarin Vaginal Cream,2002 Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicityFertil Steril 78: 469–472PubMedCrossRefGoogle Scholar
  25. 25.
    Bjarnason NH, Christiansen C 2000 Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal womenBone 26: 561–569PubMedCrossRefGoogle Scholar
  26. 26.
    Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J 2004 Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture riskBone 34: 344–351PubMedCrossRefGoogle Scholar
  27. 27.
    Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C 2002 Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fastingBone 31: 57–61PubMedCrossRefGoogle Scholar
  28. 28.
    Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR, Longcope C, Endogenous Hormones Breast Cancer Collaborative Group, 2003 Body mass index, serum sex hormones, and breast cancer risk in postmenopausal womenJ Natl Cancer Inst 95: 1218–1226PubMedGoogle Scholar
  29. 29.
    Sowers M, Derby C, Jannausch ML, Torrens JI, Pasternak R 2003 Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWANJ Clin Endocrinol Metab 88: 4904–4910PubMedCrossRefGoogle Scholar
  30. 30.
    Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI, Postmenopausal Estrogen/Progestin Intervention Trial 2003 Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the postmenopausal estrogen/progestin intervention trialJ Clin Endocrinol Metab 88: 1646–1652PubMedCrossRefGoogle Scholar
  31. 31.
    Tufano A, Marzo P, Enrini R, Morricone L, Caviezel F, Ambrosi B 2004 Anthropometric, hormonal and biochemical differences in lean and obese women before and after menopauseJ Endocrinol Invest 27: 648–653PubMedGoogle Scholar
  32. 32.
    Lonning PE, Helle SI, Johannessen DC, Adlercreutz H, Lien EA, Tally M, Ekse D, Fotsis T, Anker GB, Hall K 1995 Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patientsClin Endocrinol (Oxf) 42: 23–30CrossRefGoogle Scholar
  33. 33.
    Christodoulakos G, Lambrinoudaki I, Panoulis C, Sioulas V, Rizos D, Caramalis G, Botsis D, Creatsas G 2005 Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifeneMaturitas 50: 321–330PubMedCrossRefGoogle Scholar
  34. 34.
    Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S, Dossus L, Micheli A, Arslan A, Lenner P, Shore RE, Krogh V, Koenig KL, Riboli E, Berrino F, Hallmans G, Stattin P, Toniolo P, Kaaks R 2004 Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy womenEur J Endocrinol 150: 161–171PubMedCrossRefGoogle Scholar
  35. 35.
    Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE 1998 Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal womenJ Natl Cancer Inst 90: 1292–1299PubMedCrossRefGoogle Scholar
  36. 36.
    Dorgan JF, Baer DJ, Albert PS, Judd JT, Brown ED, Corle DK, Campbell WS, Hartman TJ, Tejpar AA, Clevidence BA, Giffen CA, Chandler DW, Stanczyk FZ, Taylor PR 2001 Serum hormones and the alcohol-breast cancer association in postmenopausal womenJ Natl Cancer Inst 93: 710–715PubMedCrossRefGoogle Scholar
  37. 37.
    Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, Pelletier G 2003 Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosteroneEndocr Rev 24: 152–182PubMedCrossRefGoogle Scholar
  38. 38.
    Bajetta E, Martinetti A, Zilembo N, Pozzi P, La Torre I, Ferrari L, Seregni E, Longarini R, Salvucci G, Bombardieri E 2002 Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolismAnn Oncol 13: 1059–1066PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Harriet Johansson
    • 1
  • Bernardo Bonanni
    • 1
  • Frederique Mariette
    • 1
  • Massimiliano Cazzaniga
    • 1
  • Laura Baglietto
    • 6
  • Aliana Guerrieri-Gonzaga
    • 1
  • Maria Teresa Sandri
    • 2
  • Alberto Luini
    • 3
  • Giuseppe Pelosi
    • 4
    • 5
  • Andrea Decensi
    • 1
    • 7
    • 8
  1. 1.Division of ChemopreventionEuropean Institute of OncologyMilanItaly
  2. 2.Laboratory MedicineEuropean Institute of OncologyMilanItaly
  3. 3.Division of Breast SurgeryEuropean Institute of OncologyMilanItaly
  4. 4.Division of PathologyEuropean Institute of OncologyMilanItaly
  5. 5.University of Milan School of MedicineMilanItaly
  6. 6.Cancer Epidemiology CentreThe Cancer Council VictoriaMelbourneAustralia
  7. 7.Division of Medical and Preventive OncologyGalliera HospitalGenoaItaly
  8. 8.Division of ChemopreventionEuropean Institute of OncologyMilanItaly

Personalised recommendations